Harmonet (Ethinylestradiol, Gestodene)

Harmonet is indicated for the prevention of pregnancy in women of reproductive age who choose an oral hormonal method.

• As a combined oral contraceptive for typical 21‑day cycles.
• For cycle regulation and reduction of menstrual‑related symptoms.
• As part of a prescribed contraceptive regimen following medical evaluation.
• May be used in women without contraindications to estrogen‑containing contraceptives.
• Provides a reversible method of birth control when taken as directed.
• Can be combined with non‑hormonal barrier methods for added protection against sexually transmitted infections.
• Suitable for women who desire a predictable menstrual pattern and are able to adhere to daily dosing.

Like other combined oral contraceptives, Harmonet may cause a range of side effects, most of which are mild and transient, typically occurring during the first few cycles as the body adjusts to the hormones.

Common

• Nausea or mild gastrointestinal discomfort.
• Breast tenderness or enlargement.
• Headache or mild migraine.
• Irregular spotting or breakthrough bleeding.
• Mood changes or mild depression.
• Weight gain or fluid retention.
• Decreased libido or sexual desire changes.
• Skin changes such as acne or melasma.

Serious

• Deep vein thrombosis, pulmonary embolism, or other thromboembolic events.
• Severe hypertension or cardiovascular complications.
• Allergic reactions such as rash, itching, or swelling.
• Liver dysfunction or jaundice.
• Severe abdominal pain indicating possible ectopic pregnancy.

Before prescribing Harmonet, clinicians assess individual risk factors and contraindications to ensure safe use.

• Contraindicated in women who are pregnant, breastfeeding, or have known or suspected pregnancy.
• Not for use in individuals with a history of thromboembolic disorders, stroke, or myocardial infarction.
• Caution in smokers over 35 years of age due to increased cardiovascular risk.
• Avoid in patients with uncontrolled hypertension, liver disease, or estrogen‑dependent tumors.
• Review any history of migraine with aura before initiating therapy.
• Assess for gallbladder disease or severe diabetes complications.
• Ensure patient can adhere to daily dosing schedule.

Harmonet can interact with several medicines, affecting its efficacy or increasing the risk of adverse events.

Avoid

• Combined hormonal contraceptives with other estrogen‑containing products (e.g., hormone replacement therapy) – may increase estrogen exposure.
• Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, or St. John’s wort – may reduce contraceptive effectiveness.
• Certain antiviral agents (e.g., protease inhibitors) that alter hormone metabolism – may require alternative contraception.

Use with caution

• Antifungal azoles (ketoconazole, itraconazole) – may increase hormone levels.
• Antidepressants like sertraline – may affect bleeding patterns.
• Anticonvulsants with moderate enzyme induction (e.g., valproate) – monitor for reduced efficacy.
• Herbal supplements such as ginseng – limited data, monitor closely.